INCYIncyte
$112.81+31% 1Y
$112.81
$81.6652 weeks$129.88
The financials
Incyte by the numbers
Incyte (INCY) reported revenue of $1.27B in Q1 2026 (quarter ended Mar 31, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 92% and net income of $303M (24% of revenue). For the full year FY2025, revenue was $5.14B (+21% year on year) and net income $1.29B. Its largest product in Jun 2026 was JAKAFI at $817M, 48% of the disclosed total, well ahead of OPZELURA at 26%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $1.27B | $1.05B | +21% |
| Gross profit | $1.17B | $980M | +19% |
| Operating income | $301M | $205M | +47% |
| Net income | $303M | $158M | +92% |
| Diluted EPS | $1.47 | $0.80 | +84% |
| Product | Revenue | Share |
|---|---|---|
| JAKAFI | $817M | 48% |
| OPZELURA | $450M | 26% |
| JAKAVI Royalty | $124M | 7.2% |
| NIKTIMVO | $60M | 3.5% |
| MINJUVIMONJUVI | $54M | 3.1% |
| ZYNYZ | $50M | 2.9% |
| OLUMIANT | $39M | 2.2% |
| OLUMIANT Royalty | $38M | 2.2% |
| ICLUSIG | $34M | 2.0% |
| PEMAZYRE | $23M | 1.4% |
| Milestone And Contract | $11M | 0.7% |
| TABRECTA | $6.7M | 0.4% |
| TABRECTA Royalty | $6.7M | 0.4% |
| Other Product Royalty | $5.3M | 0.3% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.72B (+31%)
ZYNYZ grew +460% year on yearTABRECTA Royalty +0.89% year on year
Segment Latestquarter on quarteryear on year
- JAKAFI$816.7M$816.7Mquarter on quarter +7.8%year on year +6.9%+7.8%+6.9%
- OPZELURA$449.7M$449.7Mquarter on quarter +214%year on year +173%+214%+173%
- JAKAVI Royalty$124.2M$124.2Mquarter on quarter +18%year on year +13%+18%+13%
- NIKTIMVO$60.3M$60.3Mquarter on quarter +9.5%year on year +67%+9.5%+67%
- MINJUVIMONJUVI$53.7M$53.7Mquarter on quarter +9.1%year on year +72%+9.1%+72%
- ZYNYZ$49.9M$49.9Mquarter on quarter +21%year on year +460%+21%+460%
- OLUMIANT$38.5M$38.5Mquarter on quarter +5.8%year on year +15%+5.8%+15%
- OLUMIANT Royalty$38.5M$38.5Mquarter on quarter +5.7%year on year +15%+5.7%+15%
- ICLUSIG$34.4M$34.4Mquarter on quarter -3.0%year on year +5.1%-3.0%+5.1%
- PEMAZYRE$23.4M$23.4Mquarter on quarter +3.9%year on year +5.5%+3.9%+5.5%
- Milestone And Contract$11.2M$11.2Mquarter on quarter -34%year on year +124%-34%+124%
- TABRECTA$6.7M$6.7Mquarter on quarter +12%year on year +1.5%+12%+1.5%
- TABRECTA Royalty$6.7M$6.7Mquarter on quarter +12%year on year +0.89%+12%+0.89%
- Other Product Royalty$5.3M$5.3Mquarter on quarter +64%year on year +314%+64%+314%
Biotechnology
The closest names by size in the same industry